Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Alessi
Dario Alessi, Dundee GB
| Patent application number | Description | Published |
|---|---|---|
| 20080213240 | RAC-PK as a therapeutic agent or in diagnostics, screening method for agents and process for activating RAC-PK - The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and/or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor. | 09-04-2008 |
| 20090142784 | METHODS - A method for identifying a compound expected to be useful in modulating a LRRK2 protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates the protein kinase activity of a LRRK2 polypeptide on a substrate Ezrin/Radixin/moesin (ERM) family polypeptide and (2) selecting a compound which modulates the LRRK2 polypeptide protein kinase activity. Such a compound may be useful in treating Parkinson's Disease or Parkinsonism. A catalytically active fragment of LRRK2 is identified, requiring the GTPase, COR and kinase domains as well as the WD_40-like motif and C-terminal tail. | 06-04-2009 |
| 20100047823 | Polypeptides - The use of polypeptides capable of binding to PtdIns(3,4)P | 02-25-2010 |
| 20100068742 | Methods - A method for identifying a compound expected to be useful in modulating, for example inhibiting, LRRK2 protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates, for example inhibits, the protein kinase activity of a LRRK2 polypeptide on a substrate polypeptide and (2) selecting a compound which modulates, for example inhibits, the said LRRK2 polypeptide protein kinase activity, wherein the substrate polypeptide comprises the sequence (W/F/R/K)(W/F/R/K)(R/K)(F/W/H/R)(Y/W/R)( | 03-18-2010 |
| 20110256062 | Methods - A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method may comprise or further comprise the step of assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the subcellular location of LRRK2. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems. | 10-20-2011 |
| 20110256553 | Methods - A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems. | 10-20-2011 |
Dario Alessi, Basel CH
| Patent application number | Description | Published |
|---|---|---|
| 20110275102 | ACTIVATION OF MUTATED RAC-PK - The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and/or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor. | 11-10-2011 |
Dario Renato Alessi, Dundee GB
| Patent application number | Description | Published |
|---|---|---|
| 20100093027 | Enzyme - The present invention provides for a substantially pure human or rabbit 3-phosphoinositide-dependent protein kinase. | 04-15-2010 |
Dario Renato Alessi, Scotland GB
| Patent application number | Description | Published |
|---|---|---|
| 20080286809 | Methods - A method for identifying a compound expected to be useful in modulating a WNK (With No Lysine Kinase) isoform protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates the protein kinase activity of a WNK isoform polypeptide on the substrate SPAK (STE20/SPS1-related Proline-Alanine-rich Kinase) or OSR1 (Oxidative Stress Response kinase-1) and (2) selecting a compound which modulates the said WNK isoform polypeptide protein kinase activity. Such a compound may be useful as an antihypertensive agent or for the treatment of, for example, Gordon's syndrome. | 11-20-2008 |
Donald Paul Alessi, Vancouver CA
| Patent application number | Description | Published |
|---|---|---|
| 20100183936 | MODULAR FUEL CELL POWER SYSTEM - A modular fuel cell power system includes a coolant source, a reactant source and a plurality of fuel cell modules. Each of the fuel cell modules includes a fuel cell stack and a fluid distribution plant in fluid communication with the reactant source, coolant source and fuel cell stack. The fluid distribution plant controls the flow of reactant between the reactant source and fuel cell stack. The fuel cell stacks are configured to be selectively electrically connected. | 07-22-2010 |
Enrico Alessi, Catania IT
| Patent application number | Description | Published |
|---|---|---|
| 20120040856 | METHOD FOR DETECTING THE PRESENCE OF LIQUIDS IN A MICROFLUIDIC DEVICE, DETECTING APPARATUS AND CORRESPONDING MICROFLUIDIC DEVICE - A method for detecting the presence of liquids includes detecting an initial temperature in a channel accommodating a liquid; heating the channel for a pre-determined test time; detecting a test temperature; determining a temperature variation on the basis of the initial temperature, the test temperature, and the test time; and comparing the temperature variation with at least one threshold. Before detecting an initial temperature, an ambient temperature is read, the channel is heated to the initial temperature, and is kept at the initial temperature for a time period. | 02-16-2012 |
Marzio Alessi, Torino IT
| Patent application number | Description | Published |
|---|---|---|
| 20080316914 | Method and System for Fault and Performance Recovery in Communication Networks, Related Network and Computer Program Product Therefor - A system for fault and performance recovery in a communication network includes a set of network apparatuses as well as a plurality of sites connected by means of connections having a given topology. The network also includes routers for implementing given routing policies and has associated therewith at least one database maintaining information regarding the network apparatuses. The system includes test modules for executing performance tests created automatically by exploiting the information available on the topology of the connections between the various sites and by accessing the database in question. The test modules are configured for analysing the results of the performance tests to detect possible fault and performance impairment conditions of the network. In the presence of a fault and performance impairment condition detected in the network, the routers modify the routing policy to compensate for the fault and performance impairment condition. | 12-25-2008 |